Evaluation of the Efficacy of Clostridium Butyricum CBM588® on Symptoms and Quality of Life in Patients With Diarrhea-dominant Irritable Bowel Syndrome (PROREDI: (PRObiotic REmedy for DIarrhea)

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source

ClinicalTrials.gov

Source record ID

NCT06676514

Title field or adapter rule

{'original_value': 'Evaluation of the Efficacy of Clostridium Butyricum CBM588® on Symptoms and Quality of Life in Patients With Diarrhea-dominant Irritable Bowel Syndrome (PROREDI: (PRObiotic REmedy for DIarrhea)', 'source_field': 'protocolSection.identificationModule.officialTitle'}

Ingested At

2026-10-31T23:27:35.651332+00:00

Published At

2025-05-07T00:00:00+00:00

Record Updated At

2025-05-07

Source Retrieved At

2026-10-31T22:18:52.668840+00:00

Timestamp Basis

ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Date limitation

ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions

["IBS-D (Diarrhea-predominant)"]

protocolSection.statusModule.lastUpdatePostDateStruct

{"date": "2025-05-07", "type": "ACTUAL"}

protocolSection.identificationModule.nctId

"NCT06676514"

protocolSection.identificationModule.officialTitle

"Evaluation of the Efficacy of Clostridium Butyricum CBM588\u00ae on Symptoms and Quality of Life in Patients With Diarrhea-dominant Irritable Bowel Syndrome (PROREDI: (PRObiotic REmedy for DIarrhea)"

protocolSection.statusModule.overallStatus

"COMPLETED"

protocolSection.designModule.phases

["NA"]

protocolSection.statusModule.resultsFirstPostDateStruct

null

Study condition terms

• IBS-D (Diarrhea-predominant) (protocolSection.conditionsModule.conditions)

Interventions recorded in this study

• {'armGroupLabels': ['Probiotic group'], 'description': 'This group received probiotic Clostridium butyricum CBM588® treatment for IBS-D as three tablets daily for 8 weeks.', 'name': 'Probiotic Clostridium butyricum CBM588®', 'type': 'DIETARY_SUPPLEMENT'} (protocolSection.armsInterventionsModule.interventions[])
• {'armGroupLabels': ['Control group'], 'description': 'Patients in this group received standard of care IBS-D treatment of Trimebutine maleate maleate and followed a lactose-free, no-slag diet.', 'name': 'Standard of care IBS-D treatment', 'type': 'OTHER'} (protocolSection.armsInterventionsModule.interventions[])

An intervention appearing in a study record does not establish an effect or an approved use.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.